Precision medicine is becoming the norm in life sciences research but obstacles such as limited reimbursement for tests are hindering progress, according to a new survey.
Bristol-Myers Squibb has scored a victory against arch-rivals Merck, with a new much more convenient dosing schedule for Opdivo which could help it keep ahead in the sales race.
